In a filing, Travere Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Dube Eric M unloaded Company’s shares for reported $0.17 million on Feb 01 ’24. In the deal valued at $8.70 per share,19,122 shares were sold. As a result of this transaction, Dube Eric M now holds 350,600 shares worth roughly $2.44 million.
Then, REED ELIZABETH E sold 4,764 shares, generating $41,495 in total proceeds. Upon selling the shares at $8.71, the SVP, GC & CORPORATE SECRETARY now owns 76,270 shares.
Before that, ROTE WILLIAM E. sold 4,764 shares. Travere Therapeutics Inc shares valued at $41,495 were divested by the SENIOR VICE PRESIDENT, R&D at a price of $8.71 per share. As a result of the transaction, ROTE WILLIAM E. now holds 80,720 shares, worth roughly $0.56 million.
Guggenheim downgraded its Travere Therapeutics Inc [TVTX] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who increased its forecast for the stock in early December from “a Neutral” to “a Buy”. Citigroup began covering TVTX with “Neutral” recommendation on November 20, 2023. Wells Fargo revised its rating on September 22, 2023. It rated TVTX as “an Equal weight” which previously was an “an Overweight”.
Price Performance Review of TVTX
On Monday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -1.14% to $6.96. Over the last five days, the stock has lost -4.79%. Travere Therapeutics Inc shares have fallen nearly -22.58% since the year began. Nevertheless, the stocks have fallen -66.59% over the past one year. While a 52-week high of $22.75 was reached on 01/10/24, a 52-week low of $5.25 was recorded on 04/05/24. SMA at 50 days reached $8.02, while 200 days put it at $10.08. A total of 0.53 million shares were traded, compared to the trading of 1.25 million shares in the previous session.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 6.88, which if violated will result in even more drops to 6.80. On the upside, there is a resistance level at 7.10. A further resistance level may holdings at 7.23. The Relative Strength Index (RSI) on the 14-day chart is 38.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.39%. Stochastics %K at 15.39% indicates the stock is a buying.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on Mar 15, 2024, growing by 0.31 million shares to a total of 10.07 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 9.76 million shares. There was a rise of 3.08%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 13.30% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.98.
